Premium Weekly Newsletter
BioDeal Weekly
Premium analysis of global biotech M&A, licensing, and partnerships — from official filings, not news aggregation.
Who reads this
Pharma BD professionals, biotech executives, investment bankers, and VCs tracking global deal flow and industry dynamics.
What's inside every issue
4,000-5,000 words of original analysis. 15-20 minute read.
Thesis of the Week
Deep strategic analysis of one major industry theme with data-backed investment thesis.
M&A & Acquisitions
Every pharma/biotech acquisition with deal terms from SEC filings, strategic rationale, and comparable transaction analysis.
Licensing & Partnerships
All in/out-licensing and co-development deals with upfront, milestones, royalties, territory rights, and competitive context.
Regulatory Tracker
FDA approvals, CRLs, breakthrough designations, EMA opinions, upcoming PDUFA dates.
Clinical Catalysts
Phase 3 readouts, pivotal trial initiations, key data presentations with partnering implications.
Capital & IPO Watch
Biotech IPOs from SEC S-1 filings, major funding rounds, investor profiles.
The Long View
Connecting the dots: therapeutic area heat map, emerging patterns, what to watch.
Our sources
Primary and official sources only. No competitor editorial content. Every claim links to its source.
- SEC EDGAR (8-K filings, S-1 filings)
- openFDA (drug approvals, labels)
- ClinicalTrials.gov (trial status, sponsors)
- EMA (EU marketing authorizations)
- PubMed (research papers)
- GlobeNewsWire, BusinessWire, PRNewswire (company press releases)
Why this is different
Every claim links to an official SEC filing, FDA record, or company press release. No news aggregation — original analysis built from primary data.
Thesis-driven
Not news. Investment thesis for every deal.
Zero hallucination
Every claim links to an official source.
Primary sources
Official filings, not news aggregation.
Start reading BioDeal Weekly
$69/month. Cancel anytime.